References

  1. Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol. 2005;16(6):869-877. PubMed | Google Scholar

  2. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J ClinOncol. 2003;21(11):2059-2069. PubMed | Google Scholar

  3. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351. PubMed | Google Scholar

  4. Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B et al. Oxaliplatin, irinotecan and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol. 2009;64(5):893-899. PubMed | Google Scholar

  5. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005;1(4):249-258. PubMed | Google Scholar

  6. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE et al. Clinical course of oxaliplatin induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416-3422. PubMed | Google Scholar

  7. Beijers AJ, Mols F, Vreugdenhil GA. Systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22(7):1999-2007. PubMed | Google Scholar

  8. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29(5 Suppl 15):21-33. PubMed | Google Scholar

  9. Grothey A. Clinical management of oxaliplatin associated neurotoxicity. Clin Colorectal Cancer. 2005;5 Suppl 1:S38-S46. PubMed | Google Scholar

  10. Mols F, Beijers T, Lemmens V, Van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2 to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699-2707. PubMed | Google Scholar

  11. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-1967. PubMed | Google Scholar

  12. Berg C, Essner C, Bourderont D, Aujoulat O. Détermination d'un seuil de toxicité neurologique pour l'oxaliplatine. J Clin Pharmacy. 2001;19(4):266-271. Google Scholar

  13. Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer. 2015;16(17):7603-7606. PubMed | Google Scholar

  14. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripherical neuropathy in colorectal cancer patients treated with adjuvant folfox IV. Support Care Cancer. 2013;21(5):1313-1319. PubMed | Google Scholar

  15. Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer. 2012;11(4):275-279. PubMed | Google Scholar

  16. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253-2255. PubMed | Google Scholar

  17. Magnowska M, Izycka N, Kapola-Czyz J, Romala A, Lorek J, Spaczynski M et al. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy. Ginekol Pol. 2018;89(4):200-4. PubMed | Google Scholar

  18. Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer. 2012;20(7):1491-7. PubMed | Google Scholar

  19. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P et al. Phase III randomized, placebo-controlled, double blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity. J ClinOncol. 2014;32(10):997-1005. PubMed | Google Scholar

  20. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer. J Clin Oncol. 2011;29(4):421-427. PubMed | Google Scholar

  21. Balayssac D, Ferrier J, Pereira B, Gillet B, Pétorin C, Vein J et al. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ. 2015;5(4):e007479. PubMed | Google Scholar

  22. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L et al. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;22(8):2281-95. PubMed | Google Scholar